Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.
Tomoko JogoYoshiaki NakamuraKohei ShitaraHideaki BandoHisateru YasuiTaito EsakiTetsuji TerazawaTaroh SatohEiji ShinozakiTomohiro NishinaYu SunakawaYoshito KomatsuHiroki HaraEiji OkiNobuhisa MatsuhashiTakashi OhtaTakeshi KatoKoushiro OhtsuboTakeshi KawakamiNaohiro OkanoYoshiyuki YamamotoTakanobu YamadaAkihito TsujiJustin I OdegaardHiroya TaniguchiToshihiko DoiSatoshi FujiiTakayuki YoshinoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
ctDNA sequencing identifies FGFR2 amplification missed by tissue testing in patients with advanced gastric cancer, and these patients may respond to FGFR inhibition. The utility of ctDNA sequencing warrants further evaluation to develop effective therapeutic strategies for patients with FGFR2-amplified advanced gastric cancer.